BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:VISEN Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies VISEN Pharmaceuticals's drugs run
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07706764-10863@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Yorvipath (palopegteriparatide): Phase 3 readout est. (NCT07706764)
DESCRIPTION:Yorvipath (palopegteriparatide)\, phase 3\, Hypoparathyroidism.
 \nStudy: A Study to Test the Effects and Safety of Palopegteriparatide in 
 Adolescents With Long-term Hypoparathyroidism\nEstimated primary completio
 n: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palop
 egteriparatide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07706764
URL:https://assetmemo.bio/drug/palopegteriparatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221851-10862@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Skytrofa (lonapegsomatropin): Phase 3 readout est. (NCT07221851)
DESCRIPTION:Skytrofa (lonapegsomatropin)\, phase 3.\nStudy: Trial Investiga
 ting the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily
  Somatropin in Children and Adolescents With Short Stature or Growth Failu
 re Due to Growth Hormone Sufficient Disorders\nEstimated primary completio
 n: February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lon
 apegsomatropin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07221851
URL:https://assetmemo.bio/drug/lonapegsomatropin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07924059-10862@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Skytrofa (lonapegsomatropin): Phase 3 readout est. (NCT07924059)
DESCRIPTION:Skytrofa (lonapegsomatropin)\, phase 3.\nStudy: Clinical Trial 
 Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin 
 in Achondroplasia\nEstimated primary completion: September 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/lonapegsomatropin#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07924059
URL:https://assetmemo.bio/drug/lonapegsomatropin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
